References: Malignant mesothelioma
detailed lead
American Joint Committee on Cancer. Pleural mesothelioma. AJCC Cancer Staging
Manual. seventh ed. New York, NY: Springer; 2010: 271-274.
Howlader N, Noone AM, Krapcho one thousand, Neyman N, Aminou R, Waldron W, Altekruse SF,
Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS,
Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2009, National Cancer
Institute. Bethesda, Dr., http://seer.cancer.gov/csr/1975_2009/, based on Nov 2011
SEER information submission, posted to the SEER spider web site, April 2012.
Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic jail cell-based
immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit
Care Med. 2010;181:1383-1390.
National Cancer Institute. Physician Data Query (PDQ). Malignant :
Treatment. 2012. Accessed at
www.cancer.gov/cancertopics/pdq/treatment/malignantmesothelioma/HealthProfessional
on August 2, 2012.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines
inward Oncology: Malignant Pleural . V.2.2012. Accessed at
www.nccn.org/professionals/physician_gls/pdf/mpm.pdf on August 2, 2012.
Pan X, Day west, Wang west, et al. Residential proximity to naturally occurring asbestos as well as
mesothelioma adventure in California. Am J Resp Crit Care. 2005;172:1019-1025.
Pass HI, Vogelzgang NJ, Hahn SM, Carbone 1000. Benign together with malignant mesothelioma. In:
DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg'sec
Cancer: Principles as well as Practice of Oncology . 9th ed. Philadelphia, Pa: Lippincott
Williams & Wilkins; 2011:2052-2080.
Price B, Ware A. trends inwards the United States: An update based on
Surveillance Epidemiology as well as End Results programme appointment for 1973-2003. Am J
Epidemiol. 2004;159:107-112.
Advertisement
